Hermetica Superfood Encyclopedia
The Short Answer
E. coli Nissle 1917 is a probiotic strain that produces microcins and colicins, antimicrobial peptides that inhibit pathogenic bacteria in the gut. This strain enhances intestinal barrier function and modulates immune responses through toll-like receptor activation.
CategoryProbiotic & Fiber
GroupOther
Evidence LevelStrong
Primary KeywordE. coli Nissle 1917 benefits
Synergy Pairings3
Escherichia coli Nissle 1917 (Mutaflor) — botanical close-up
Health Benefits
Supports gut health by inhibiting pathogenic bacteria, promoting a balanced microbiome. This can lead to improved digestive function and reduced bloating. - Enhances immune response by stimulating the production of immunoglobulins, which helps protect against infections. - Reduces symptoms of IBS by modulating gut motility, providing relief from abdominal pain and discomfort. - Supports mental health by interacting with the gut-brain axis, potentially alleviating symptoms of anxiety and depression. - Promotes skin health by reducing systemic inflammation, leading to clearer, healthier skin. - Aids in nutrient absorption by maintaining a healthy gut lining, ensuring efficient uptake of vitamins and minerals. - Supports urinary tract health by preventing the colonization of harmful bacteria, reducing the risk of infections.
Origin & History
Natural habitat
Escherichia coli Nissle 1917 is a non-pathogenic strain of E. coli isolated in 1917. It is produced through fermentation and used in probiotic supplements for gastrointestinal health.
“Discovered during World War I, Escherichia coli Nissle 1917 has been used in Europe for decades to manage gastrointestinal disorders.”Traditional Medicine
Scientific Research
Clinical studies, including RCTs, have shown that Escherichia coli Nissle 1917 is effective in maintaining remission in ulcerative colitis and improving gut health.
Preparation & Dosage
Traditional preparation
The recommended dosage is typically one capsule per day. Consult a healthcare provider before use.
Nutritional Profile
Escherichia coli Nissle 1917 (EcN) is a probiotic bacterium, not a conventional food ingredient, so it does not contribute macronutrients (carbohydrates, fats, proteins) or micronutrients in meaningful dietary quantities at therapeutic doses. Key bioactive components include: (1) Lipopolysaccharides (LPS) in the outer membrane, which at low, controlled doses stimulate innate immune signaling via TLR4 pathways without inducing systemic inflammation; (2) Flagellin proteins that activate TLR5-mediated immune responses; (3) Short-chain fatty acid (SCFA) precursors — EcN ferments available substrates to produce acetate and formate, contributing indirectly to butyrate production by cross-feeding colonic bacteria; (4) Microcins (low-molecular-weight antimicrobial peptides, notably microcins M and H47) that competitively inhibit pathogenic Enterobacteriaceae; (5) Siderophores (aerobactin, enterobactin) involved in iron chelation, which reduce iron availability for competing pathogens; (6) Colanic acid and other exopolysaccharides in the capsule that promote biofilm formation and colonization resistance. Typical therapeutic dosage in commercial Mutaflor capsules is 2.5×10^8 to 25×10^9 CFU per capsule. Protein content of the bacterial cell mass is approximately 50–60% of dry weight (predominantly structural and enzymatic proteins), but this is not bioavailable in a nutritional sense at probiotic doses. Bioavailability note: The strain is acid-sensitive and Mutaflor uses an enteric-coated capsule to ensure gastric acid bypass, with viable delivery to the colon estimated at 10–40% of ingested CFU depending on gastrointestinal transit conditions.
How It Works
Mechanism of Action
E. coli Nissle 1917 produces microcins H47 and M, along with colicins Ia and Ib, which target pathogenic bacteria by disrupting their cell membranes. The strain activates toll-like receptors 2 and 4 on intestinal epithelial cells, triggering NF-κB signaling pathways that enhance antimicrobial peptide production. It also stimulates secretory IgA production and strengthens tight junctions through upregulation of claudin and occludin proteins.
Clinical Evidence
Clinical trials involving 200-300 participants show E. coli Nissle 1917 reduces IBS symptom severity by 40-60% compared to placebo over 6-12 weeks. Studies demonstrate 65-85% remission rates in ulcerative colitis maintenance therapy, comparable to mesalazine. Randomized controlled trials indicate significant reductions in pathogenic bacteria counts and improved intestinal permeability markers. Evidence quality is moderate to high for digestive conditions but limited for immune benefits.
Safety & Interactions
E. coli Nissle 1917 is generally well-tolerated with mild side effects including temporary bloating or gas in 5-15% of users during initial weeks. It may interact with immunosuppressive medications by potentially reducing their effectiveness through immune stimulation. The strain is contraindicated in severely immunocompromised individuals and those with central venous catheters due to bacteremia risk. Safety during pregnancy and breastfeeding has not been established through clinical trials.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Escherichia coli Nissle 1917EcNDSM 6601Mutaflor strainNissle 1917E. coli NissleProbiotic E. coli
Frequently Asked Questions
What is the typical dosage of E. coli Nissle 1917?
The standard dosage ranges from 2.5-25 billion CFU daily, typically taken as 1-2 capsules with meals. Most clinical studies use 2.5-10 billion CFU daily for maintenance therapy in digestive conditions.
How long does it take for E. coli Nissle 1917 to work?
Initial colonization occurs within 1-2 weeks, but therapeutic benefits typically emerge after 4-6 weeks of consistent use. Maximum benefits for IBS and digestive symptoms are usually observed after 8-12 weeks.
Can E. coli Nissle 1917 be taken with antibiotics?
It should be separated from antibiotic doses by at least 2-3 hours to prevent bacterial killing. Many practitioners recommend starting or resuming E. coli Nissle 1917 supplementation after completing antibiotic courses.
Is E. coli Nissle 1917 safe for children?
Clinical studies have demonstrated safety in children as young as 1 year old for specific digestive conditions. However, pediatric dosing should be supervised by healthcare providers and typically uses lower CFU counts than adult formulations.
What makes E. coli Nissle 1917 different from other probiotics?
Unlike typical Lactobacillus or Bifidobacterium strains, this E. coli strain produces specific antimicrobial compounds called microcins and colicins. It also has unique capacity for long-term gut colonization and direct pathogen inhibition through competitive mechanisms.
Does E. coli Nissle 1917 help with IBS symptoms, and what is the clinical evidence?
Clinical studies demonstrate that E. coli Nissle 1917 (Mutaflor) is effective for reducing IBS symptoms, particularly abdominal pain and irregular bowel movements, through modulation of gut motility and the intestinal barrier. Multiple randomized controlled trials show comparable efficacy to standard probiotics, with improvements typically observed within 2-4 weeks of consistent use. The evidence is particularly strong for IBS-D (diarrhea-predominant) and mixed-type IBS presentations.
Who should avoid E. coli Nissle 1917, and are there any contraindications?
While generally safe, E. coli Nissle 1917 should be avoided by immunocompromised individuals (including those on immunosuppressants or with severe immunodeficiency) due to theoretical risk of translocation. Patients with inflammatory bowel disease should consult their healthcare provider before use, as responses vary individually. Those with a documented allergy to E. coli or lactose intolerance (some formulations contain lactose) should also avoid this supplement.
How does E. coli Nissle 1917 support gut barrier function and immune health?
E. coli Nissle 1917 strengthens the intestinal barrier by producing short-chain fatty acids and defensins, which reinforce tight junctions between gut cells and reduce intestinal permeability. It simultaneously stimulates the production of immunoglobulins (particularly IgA) that protect mucosal surfaces from pathogenic bacteria and toxins. This dual mechanism not only improves digestive health but also supports systemic immune function through enhanced gut-associated lymphoid tissue activation.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w escherichia-coli-nissle-1917-mutaflor curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
